BRPI0417838A - derivados de tetrahidroquinolina substituìdos por 2-(hetero) arila - Google Patents
derivados de tetrahidroquinolina substituìdos por 2-(hetero) arilaInfo
- Publication number
- BRPI0417838A BRPI0417838A BRPI0417838-6A BRPI0417838A BRPI0417838A BR PI0417838 A BRPI0417838 A BR PI0417838A BR PI0417838 A BRPI0417838 A BR PI0417838A BR PI0417838 A BRPI0417838 A BR PI0417838A
- Authority
- BR
- Brazil
- Prior art keywords
- nnr
- nar
- halo
- aryl
- coor
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 title abstract 2
- 125000005842 heteroatom Chemical group 0.000 title 1
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 8
- -1 (CY 2) n-Q 1> Chemical group 0.000 abstract 4
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical class C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 abstract 4
- VIESAWGOYVNHLV-UHFFFAOYSA-N 1,3-dihydropyrrol-2-one Chemical compound O=C1CC=CN1 VIESAWGOYVNHLV-UHFFFAOYSA-N 0.000 abstract 3
- 230000000394 mitotic effect Effects 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- OALXTMWCXNPUKJ-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,5-naphthyridine Chemical class C1=CN=C2CCCNC2=C1 OALXTMWCXNPUKJ-UHFFFAOYSA-N 0.000 abstract 2
- LXCHFFXACSHXRY-UHFFFAOYSA-N 1-butyl-2-thiophen-3-yl-3,4-dihydro-2H-quinoline Chemical class C(CCC)N1C(CCC2=CC=CC=C12)C1=CSC=C1 LXCHFFXACSHXRY-UHFFFAOYSA-N 0.000 abstract 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 abstract 2
- 101150065749 Churc1 gene Proteins 0.000 abstract 2
- 102100038239 Protein Churchill Human genes 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000175 2-thienyl group Chemical class S1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- HGFMFKSDOFFKRV-UHFFFAOYSA-N 8h-pyrano[2,3-h]quinoline Chemical class C1=CC=NC2=C(C=CCO3)C3=CC=C21 HGFMFKSDOFFKRV-UHFFFAOYSA-N 0.000 abstract 1
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 abstract 1
- 230000004668 G2/M phase Effects 0.000 abstract 1
- 241000972349 Ocoa Species 0.000 abstract 1
- YKOWBJJOJNGCAD-SHYZEUOFSA-N [(2r,3s,5r)-3-hydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical compound O=C1N=C(NO)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 YKOWBJJOJNGCAD-SHYZEUOFSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 230000022131 cell cycle Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000004970 halomethyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002962 imidazol-1-yl group Chemical class [*]N1C([H])=NC([H])=C1[H] 0.000 abstract 1
- 125000004283 imidazolin-2-yl group Chemical group [H]N1C(*)=NC([H])([H])C1([H])[H] 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 229940126261 motor protein inhibitor Drugs 0.000 abstract 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 abstract 1
- 229960004448 pentamidine Drugs 0.000 abstract 1
- 229940076155 protein modulator Drugs 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 125000002112 pyrrolidino group Chemical class [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10360154A DE10360154A1 (de) | 2003-12-20 | 2003-12-20 | Tetrahydrochinoline |
| US53996104P | 2004-01-30 | 2004-01-30 | |
| DE102004026026A DE102004026026A1 (de) | 2004-05-27 | 2004-05-27 | Tetrahydrochinoline |
| PCT/EP2004/014205 WO2005063735A1 (de) | 2003-12-20 | 2004-12-14 | 2- (hetero) -arylsubstituierte tetrahydrochinolinderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0417838A true BRPI0417838A (pt) | 2007-04-17 |
Family
ID=43969203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0417838-6A BRPI0417838A (pt) | 2003-12-20 | 2004-12-14 | derivados de tetrahidroquinolina substituìdos por 2-(hetero) arila |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7868172B2 (https=) |
| EP (2) | EP2033959B1 (https=) |
| JP (1) | JP5237555B2 (https=) |
| AT (2) | ATE507220T1 (https=) |
| AU (1) | AU2004309028B9 (https=) |
| BR (1) | BRPI0417838A (https=) |
| CA (1) | CA2550350C (https=) |
| DE (1) | DE502004012458D1 (https=) |
| DK (2) | DK2033959T3 (https=) |
| ES (1) | ES2315727T3 (https=) |
| PL (2) | PL1761515T3 (https=) |
| PT (2) | PT1761515E (https=) |
| SI (2) | SI1761515T1 (https=) |
| WO (1) | WO2005063735A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| GB0425854D0 (en) * | 2004-11-25 | 2004-12-29 | Astrazeneca Ab | Therapeutic treatment |
| DE102005027170A1 (de) * | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Substituierte Tetrahydrochinoline |
| US7875721B2 (en) | 2005-08-04 | 2011-01-25 | Stc.Unm | Compounds for binding to ERα/β and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof |
| CA2656064C (en) | 2006-06-19 | 2013-11-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Polymorphic forms and process |
| DE102007013856A1 (de) | 2007-03-20 | 2008-09-25 | Merck Patent Gmbh | Substituierte Tetrahydropyrrolochinoline |
| DE102007013854A1 (de) | 2007-03-20 | 2008-09-25 | Merck Patent Gmbh | Tetrahydrochinoline |
| DE102007013855A1 (de) * | 2007-03-20 | 2008-09-25 | Merck Patent Gmbh | Substituierte Tetrahydrochinoline |
| DE102007021862A1 (de) * | 2007-05-10 | 2008-11-13 | Merck Patent Gmbh | Wässrige pharmazeutische Zubereitung |
| CN101873848B (zh) * | 2007-07-19 | 2014-12-10 | 帝斯曼知识产权资产管理有限公司 | 亲脂性健康成分的可片剂化制剂 |
| EP2220067A2 (en) | 2007-12-18 | 2010-08-25 | Merck Patent GmbH | Process for preparing tetrahydroquinoline derivatives |
| US20100280070A1 (en) * | 2008-01-04 | 2010-11-04 | Akkinepally Raghuram Rao | Novel tetrahydroquinolines as aromatase inhibitors |
| WO2011009523A1 (en) | 2009-07-24 | 2011-01-27 | Merck Patent Gmbh | Eg5 as biomarker in rare thoracic cancer |
| EP2620438A1 (en) * | 2012-01-24 | 2013-07-31 | Laboratorios Del. Dr. Esteve, S.A. | Substituted pyrano and furanoquinolines, their preparation and use as medicaments |
| EP2647638A1 (en) * | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Substituted tricyclic compounds with activity towards ep1 receptors |
| US9498540B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
| RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
| CN110627770A (zh) | 2013-11-18 | 2019-12-31 | 福马疗法公司 | 作为bet溴域抑制剂的四氢喹啉组成物 |
| WO2017214468A1 (en) | 2016-06-09 | 2017-12-14 | Tien Yang Der | Nanodroplet compositions for the efficient delivery of anti-cancer agents |
| CN110684031B (zh) * | 2019-08-14 | 2021-07-02 | 西北大学 | 一种反式-四氢呋喃/吡喃并四氢喹啉衍生手性化合物的不对称合成方法 |
| WO2022006365A2 (en) * | 2020-07-02 | 2022-01-06 | Purdue Research Foundation | Tetrahydro-3h-pyrazolo quinolone and tetrahydro-3h-pyrrolo[3,2-f]quinoline-containing compounds and uses thereof |
| EP4269392A4 (en) | 2020-12-25 | 2025-01-29 | Toray Industries, Inc. | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICAL USE THEREOF |
| AU2023286251A1 (en) | 2022-06-24 | 2024-12-05 | Toray Industries, Inc. | Therapeutic agent or prophylactic agent for amyotrophic lateral sclerosis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100310939B1 (ko) * | 1992-10-01 | 2002-06-20 | 추후제출 | 태그로암호화한복합조합화학라이브러리 |
| CN1154640C (zh) * | 1993-10-01 | 2004-06-23 | 纽约市哥伦比亚大学理事 | 用标示物编码的多元组合化学库 |
| EP1187633A4 (en) | 1999-04-08 | 2005-05-11 | Arch Dev Corp | USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY |
| AU7558900A (en) * | 1999-10-14 | 2001-04-23 | Kaken Pharmaceutical Co., Ltd. | Tetrahydroquinoline derivatives |
| MXPA03008691A (es) * | 2001-03-29 | 2003-12-12 | Bristol Myers Squibb Co | Metodo para tratamiento de enfermedades proliperativas usando inhibidores eg5. |
| US7250423B2 (en) * | 2001-09-24 | 2007-07-31 | Chao-Jun Li | Methods for synthesizing heterocycles and therapeutic use of the heterocycles for cancers |
| DE10236910A1 (de) * | 2002-08-12 | 2004-03-11 | Grünenthal GmbH | Substituierte 1,2,3,4-Tetrahydrochinolinderivate |
-
2004
- 2004-12-14 EP EP08014660A patent/EP2033959B1/de not_active Expired - Lifetime
- 2004-12-14 AT AT08014660T patent/ATE507220T1/de active
- 2004-12-14 DK DK08014660.8T patent/DK2033959T3/da active
- 2004-12-14 AT AT04803833T patent/ATE413393T1/de active
- 2004-12-14 DK DK04803833T patent/DK1761515T3/da active
- 2004-12-14 PL PL04803833T patent/PL1761515T3/pl unknown
- 2004-12-14 US US10/583,689 patent/US7868172B2/en not_active Expired - Fee Related
- 2004-12-14 BR BRPI0417838-6A patent/BRPI0417838A/pt not_active IP Right Cessation
- 2004-12-14 CA CA2550350A patent/CA2550350C/en not_active Expired - Fee Related
- 2004-12-14 ES ES04803833T patent/ES2315727T3/es not_active Expired - Lifetime
- 2004-12-14 PT PT04803833T patent/PT1761515E/pt unknown
- 2004-12-14 WO PCT/EP2004/014205 patent/WO2005063735A1/de not_active Ceased
- 2004-12-14 SI SI200430985T patent/SI1761515T1/sl unknown
- 2004-12-14 EP EP04803833A patent/EP1761515B1/de not_active Expired - Lifetime
- 2004-12-14 JP JP2006544304A patent/JP5237555B2/ja not_active Expired - Fee Related
- 2004-12-14 AU AU2004309028A patent/AU2004309028B9/en not_active Ceased
- 2004-12-14 PL PL08014660T patent/PL2033959T3/pl unknown
- 2004-12-14 SI SI200431714T patent/SI2033959T1/sl unknown
- 2004-12-14 DE DE502004012458T patent/DE502004012458D1/de not_active Expired - Lifetime
- 2004-12-14 PT PT08014660T patent/PT2033959E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2033959B1 (de) | 2011-04-27 |
| ES2315727T3 (es) | 2009-04-01 |
| US7868172B2 (en) | 2011-01-11 |
| EP1761515B1 (de) | 2008-11-05 |
| CA2550350C (en) | 2013-03-12 |
| ATE507220T1 (de) | 2011-05-15 |
| PT1761515E (pt) | 2009-02-11 |
| DK1761515T3 (da) | 2009-02-16 |
| EP2033959A1 (de) | 2009-03-11 |
| PL1761515T3 (pl) | 2009-04-30 |
| EP1761515A1 (de) | 2007-03-14 |
| DE502004012458D1 (de) | 2011-06-09 |
| SI2033959T1 (sl) | 2011-08-31 |
| JP5237555B2 (ja) | 2013-07-17 |
| AU2004309028B9 (en) | 2011-06-16 |
| AU2004309028A1 (en) | 2005-07-14 |
| SI1761515T1 (sl) | 2009-02-28 |
| CA2550350A1 (en) | 2005-07-14 |
| PT2033959E (pt) | 2011-07-29 |
| PL2033959T3 (pl) | 2011-09-30 |
| DK2033959T3 (da) | 2011-07-25 |
| JP2007515419A (ja) | 2007-06-14 |
| WO2005063735A1 (de) | 2005-07-14 |
| US20070203167A1 (en) | 2007-08-30 |
| ATE413393T1 (de) | 2008-11-15 |
| AU2004309028B2 (en) | 2011-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0417838A (pt) | derivados de tetrahidroquinolina substituìdos por 2-(hetero) arila | |
| RU2217421C2 (ru) | Производные индола, обладающие антивирусной активностью | |
| AU2017382436B2 (en) | Compounds and methods for the targeted degradation of Rapidly Accelerated Fibrosarcoma polypeptides | |
| NO20051870L (no) | 1H-1,2,4-triazol-3-karboksamidderivater som cannabinoid-CB1-reseptorligander | |
| TW200517388A (en) | Thiazole derivatives as cannabinoid receptor modulators | |
| ZA200500253B (en) | Ketones | |
| HK33189A (en) | 1,2,3,9-tetrahydro-3-(imidazol-1-ylmethyl)-4h-carbazol-4-one derivatives | |
| TR200102054T2 (tr) | Pirazolkarboksilik asit türevleri, hazırlanmaları ve bunları içeren farmasötik kompozisyonlar. | |
| FR2886136B1 (fr) | Composition pour la teinture des fibres keratiniques comprenant au moins un derive de diamino-n,n-dihydro- pyrazolone et un colorant d'oxydation cationique | |
| NO991384L (no) | Substituerte heterocykler som anti-tumormidler | |
| HRP20060286T3 (en) | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | |
| ATE421524T1 (de) | 5-ring-heterocyclen, ihre herstellung, ihre verwendung als inhibitoren der leukozytenadhäsion und sie enthaltende pharmazeutische präparate | |
| PH12022553516A1 (en) | Novel pyrazole derivatives | |
| HUT77363A (hu) | 5-Lipoxigenáz inhibitor hatású azolszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| Takeuchi et al. | 1, 2-disubstituted indole, azaindole and benzimidazole derivatives possessing amine moiety: a novel series of thrombin inhibitors | |
| RU2003114408A (ru) | Производные 1-метилкарбапенема | |
| ATE444965T1 (de) | Sich als therapeutische mittel eignende arylalkylindole mit affinität für den serotoninrezeptor, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten | |
| NO20060191L (no) | 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)2,2-difenylacetamidderivater som muskarinreceptoragonister | |
| RU97118853A (ru) | Производные бензимидазола | |
| MXPA05011841A (es) | Metil-indoles y metil-pirrolopiridinas como agonistas adrenergicos de alfa-1. | |
| DE60309324D1 (de) | Tetracyclische arylcarbonyl indole mit serotoninrezeptoraffinität als arzneimittel, verfahren zu ihrer herstellung und pharmazeutische zubereitungen | |
| GB2066067A (en) | Antifungal compositions | |
| ZA200605022B (en) | Benzofurans and benzothiophenes | |
| MX2023012246A (es) | Nuevos derivados de pirazolo[1,5-a]pirimidina como ligandos sigma. | |
| MX2023013305A (es) | Compuesto polimorfo de imidazolidinona, método de preparación del mismo y uso del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |